It was found that for ARDS, using CRRT in addition to conventional therapy can reduce the mortality rate (I2 = 0%; RR: 0.40; 95% CI: 0.30–0.53; p < 0.01), the incidence of VAP (I2 = 0%; RR: 0.44; 95% CI: 0.33–0.59; p < 0.01), ICU length of stay, mechanical ventilation time, and EVLWI at 72 h, as well as APACHE II score, TNF‐α, and IL‐6 at various time points. This evidence concerns the gene TNF and acute respiratory distress syndrome.